--- title: "PharmacoEconomics: 9 recent papers (last 30 days)" description: "PharmacoEconomics published 9 papers in the last 30 days (2026-10-01 to 2026-10-30), ranking #116 of 392 journals." url: https://scholar4ai.com/journals/pharmacoeconomics markdown_url: https://scholar4ai.com/journals/pharmacoeconomics.md license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/) share_text: "PharmacoEconomics published 9 papers in the last 30 days (2026-10-01 to 2026-10-30), ranking #116 of 392 journals." data_url: https://scholar4ai.com/data/rankings.json updated: 2026-10-30T12:46:54+09:00 window: 2026-10-01 to 2026-10-30 source: OpenAlex (CC0) --- # PharmacoEconomics - 2 papers in the last 7 days - category: Health Economics and Policy - publisher: Adis, Springer Healthcare - ISSN 1170-7690 Back to the ranking: https://scholar4ai.com/rankings/journals.md ## Key findings - PharmacoEconomics published 9 papers in the last 30 days (2026-10-01 to 2026-10-30), ranking #116 of 392 journals. - Leading institutions: Newcastle University (2), University of Maryland, Baltimore (2) and University of Exeter (2). - Countries: United Kingdom (5), United States (3) and United Arab Emirates (1). - From Oct 2023 to Sep 2026, PharmacoEconomics published 342 papers (10 a month on average, by publication date in OpenAlex). - Its most frequent keywords over that period were “cost-effectiveness” (96), “quality-adjusted life years” (80) and “health technology assessment” (75). - Its most-cited paper of the period is “A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist” (2024-09-03), with 121 citations. - Since October 2016, its most-cited paper is “The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)” (2021-05-05), with 839 citations. ## The last 36 months *Papers by publication date, Oct 2023 to Sep 2026* | Oct 23–Sep 24 | Oct 24–Sep 25 | Oct 25–Sep 26 | 36 months | |---:|---:|---:|---:| | 112 | 111 | 119 | 342 | *Most frequent keywords, Oct 2023 to Sep 2026* | # | Keyword | Papers | |---:|---|---:| | 1 | cost-effectiveness | 96 | | 2 | quality-adjusted life years | 80 | | 3 | health technology assessment | 75 | | 4 | economic evaluation | 35 | | 5 | health-related quality of life | 35 | | 6 | health care costs | 26 | | 7 | cost-effectiveness analysis | 25 | | 8 | Markov model | 24 | | 9 | cost-utility analysis | 21 | | 10 | economic burden | 19 | *Most-cited papers published Oct 2023 to Sep 2026* | # | Citations | Per month | Title | Journal | Published | Authors | |---:|---:|---:|---|---|---|---| | 1 | 121 | 4.7 | [A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist](https://doi.org/10.1007/s40273-024-01431-6) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2024-09-03 | Jemimah Ride, Ilias Goranitis, Yan Meng et al. | | 2 | 59 | 1.7 | [Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force](https://doi.org/10.1007/s40273-023-01321-3) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2023-12-02 | Edward Henry, Hareth Al‐Janabi, Werner B. F. Brouwer et al. | | 3 | 39 | 2.3 | [The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review](https://doi.org/10.1007/s40273-025-01495-y) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2025-05-21 | Sven P H Nouwens, Stella Maria Marceta, Michael Bui et al. | | 4 | 32 | 1.3 | [Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach](https://doi.org/10.1007/s40273-024-01441-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2024-10-25 | Laura Vallejo‐Torres | | 5 | 29 | 0.8 | [Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial](https://doi.org/10.1007/s40273-023-01319-x) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2023-11-10 | Junwen Zhou, Claire Williams, Mi Jun Keng et al. | ## Most-cited since October 2016 *The journal's most-cited papers published since October 2016* | # | Citations | Per month | Title | Journal | Published | Authors | |---:|---:|---:|---|---|---|---| | 1 | 839 | 12.7 | [The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)](https://doi.org/10.1007/s40273-021-01019-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-05-05 | Paul E. Greenberg, Andrée-Anne Fournier, Tammy Sisitsky et al. | | 2 | 803 | 8.4 | [Discrete Choice Experiments in Health Economics: Past, Present and Future](https://doi.org/10.1007/s40273-018-0734-2) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-11-02 | Vikas Soekhai, Esther Wilhelmina de Bekker-Grob, Alan R. Ellis et al. | | 3 | 592 | 5.7 | [German Value Set for the EQ-5D-5L](https://doi.org/10.1007/s40273-018-0615-8) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-02-19 | Kristina Ludwig, J.-Matthias Graf von der Schulenburg, Wolfgang Greiner | | 4 | 394 | 5.3 | [A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)](https://doi.org/10.1007/s40273-020-00952-0) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-08-19 | Michael Urbich, Gary A. Globe, Krystallia Pantiri et al. | | 5 | 380 | 3.6 | [Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries](https://doi.org/10.1007/s40273-018-0623-8) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-02-22 | Mathieu F. Janssen, Gouke J. Bonsel, Nan Luo | | 6 | 360 | 5.7 | [How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment](https://doi.org/10.1007/s40273-021-01065-y) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-08-08 | Michael Schlander, K. Hernández-Villafuerte, Chih‐Yuan Cheng et al. | | 7 | 355 | 3.4 | [A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D](https://doi.org/10.1007/s40273-018-0642-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-03-23 | Ines Buchholz, Mathieu F. Janssen, Thomas Kohlmann et al. | | 8 | 350 | 3.5 | [Discounting in Economic Evaluations](https://doi.org/10.1007/s40273-018-0672-z) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-05-19 | Arthur E. Attema, Werner B. F. Brouwer, Karl Claxton | | 9 | 334 | 2.9 | [Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software](https://doi.org/10.1007/s40273-017-0506-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-04-03 | Emily Lancsar, Denzil G. Fiebig, Arne Risa Hole | | 10 | 279 | 3.7 | [Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018](https://doi.org/10.1007/s40273-020-00942-2) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-07-22 | David D. Kim, Madison C. Silver, Natalia Kunst et al. | *Papers, newest first.* | Date | Title | Journal | Authors | Affiliations | |---|---|---|---|---| | 2026-10-26 | [Modelling Carer Quality-Adjusted Life-Years Into Economic Evaluations: An Evidence Assessment Group Perspective](https://doi.org/10.1007/s40273-026-01685-2) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Giovany Orozco-Leal, Louise Tanner, Eugenie Evelynne Johnson et al. | Newcastle University | | 2026-10-25 | [Measuring the Health of Young Children](https://doi.org/10.1007/s40273-026-01675-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Daniel M. Hausman | University of Wisconsin–Madison | | 2026-10-23 | [Beyond Traditional Cost-Effectiveness Analysis: Operationalizing the Equivalent Income Approach for Equity-Sensitive Health Technology Assessment](https://doi.org/10.1007/s40273-026-01676-3) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Pauline Chauvin, Clémence Thébaut | Université Paris Cité; Sorbonne University Abu Dhabi; Laboratoire Interdisciplinaire de Recherche Appliquée en Economie-Gestion et Santé; … | | 2026-10-22 | [Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness Analyses](https://doi.org/10.1007/s40273-026-01662-9) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Nabin Poudel, Leah Lodise, Jiwon Oh et al. | University of Maryland, Baltimore | | 2026-10-15 | [The Opportunity Cost of Funding High-Cost Biologics in the Context of Inequitable Access to the Fundamentals of Care: An External Assessment Group Perspective](https://doi.org/10.1007/s40273-026-01678-1) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Julia C. Whitehall, Louise Tanner, Nawaraj Bhattarai et al. | Newcastle University; Leeds Teaching Hospitals NHS Trust | | 2026-10-09 | [Waiting for Trial Evidence or Using Real-World Evidence: Trade-Offs for Coverage with Evidence Development](https://doi.org/10.1007/s40273-026-01668-3) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Boshen Jiao, Yizhi Liang, 陶立元 et al. | University of Southern California; Peking University; Peking University Third Hospital; … | | 2026-10-09 | [Methodological Challenges and Preferred Approaches for the Economic Evaluation of CAR T Therapies: Evidence Review and Expert Consensus from NICE Appraisals](https://doi.org/10.1007/s40273-026-01673-6) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Mehdi Yousefi, Amin Mehrabian, Maeve A O'Reilly et al. | University of Birmingham; University College Hospital; University of Exeter | | 2026-10-06 | [Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?](https://doi.org/10.1007/s40273-026-01672-7) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Chris Bartlett, Rachael McCool, Matthew J. Taylor | University of York | | 2026-10-06 | [Correction: Comparing User‑Written Codes for Performing Economic Evaluations in Stata](https://doi.org/10.1007/s40273-026-01663-8) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Bradley Barker-Jones, Patricia Navvuga, Petra Baji et al. | University of Bristol; University of Exeter; Southmead Hospital | ## Cite this page Scholar4AI. (2026). PharmacoEconomics. Journal Research Rankings. Retrieved October 30, 2026, from https://scholar4ai.com/journals/pharmacoeconomics ```bibtex @misc{scholar4ai-journals-pharmacoeconomics, author = {{Scholar4AI}}, title = {PharmacoEconomics}, year = {2026}, howpublished = {\url{https://scholar4ai.com/journals/pharmacoeconomics}}, urldate = {2026-10-30}, note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0} } ``` License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).